Iovance BiotherapeuticsIOVA +1.90%44 Days Payable is 64.00 as of Mar. 2026, which is 46% below its 10-year median of 118.67. GuruFocus rates IOVA with a GF Score™ of 44/100 and a GF Value™ of $18.84 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, Iovance Biotherapeutics ranks worse than 63.08% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Iovance Biotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Iovance Biotherapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Iovance Biotherapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Iovance Biotherapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Iovance Biotherapeutics (IOVA) has a Days Payable of 64.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Iovance Biotherapeutics and its competitors. This is 46% below median its historical median of 118.67. Over the past decade, Iovance Biotherapeutics' Days Payable has ranged from 52.34 to 10,551.79. According to the industry distribution chart, Iovance Biotherapeutics ranks #446 out of 707 companies in the Biotechnology industry, placing it in the top 63.1%.
Is Iovance Biotherapeutics' Days Payable too high?
Iovance Biotherapeutics' current Days Payable of 64.00 is 46% below median its 10-year median of 118.67. Over the past 10 years, this metric has ranged from a low of 52.34 to a high of 10,551.79. The Biotechnology industry median Days Payable is 113.76. Iovance Biotherapeutics' value of 64.00 is 43.7% below this industry median. Based on the distribution chart, Iovance Biotherapeutics ranks #446 out of 707 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Iovance Biotherapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Iovance Biotherapeutics' Days Payable compare to HRMY and NRIX?
According to the Biotechnology industry distribution chart, Iovance Biotherapeutics ranks #446 out of 707 companies for Days Payable. This places Iovance Biotherapeutics in the lower half of its industry. The industry median Days Payable is 113.76. Iovance Biotherapeutics' value of 64.00 is 43.7% below this benchmark. Historically, Iovance Biotherapeutics' own Days Payable has ranged from 52.34 to 10,551.79 over the past decade. While the company's 10-year median is 118.67 vs. the industry median of 113.76, Iovance Biotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Iovance Biotherapeutics's current Days Payable of 64.00 is 43.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Iovance Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iovance Biotherapeutics's current Days Payable is 64.00, which is 46% below median its own 10-year median of 118.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iovance Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Iovance Biotherapeutics (IOVA) is currently considered Possible Value Trap. The stock's GF Value™ is $18.84, compared to a current price of $4.29 — trading 77.3% below its estimated fair value. The current Days Payable is 64.00, which is 46% below median its 10-year median of 118.67 and 43.7% below the Biotechnology industry median of 113.76. Iovance Biotherapeutics' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Iovance Biotherapeutics (IOVA), the current Days Payable is 64.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Iovance Biotherapeutics (IOVA) Overvalued in 2026?
Based on GuruFocus' analysis, Iovance Biotherapeutics stock appears to be undervalued.
The current stock price of $4.29 is trading 77.3% below its estimated GF Value™ of $18.84.
GuruFocus considers Iovance Biotherapeutics to be Possible Value Trap.
Key valuation signals for IOVA:
Days Payable: 64.00 (46% below median its 10-year median of 118.67)
GF Value™: $18.84 vs. price of $4.29 (77.3% below fair value)
Industry Position: 43.7% below the Biotechnology median (#446 of 707)
No single metric tells the full story. See the IOVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
44GF Score
Get the complete analysis for IOVA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOVA has been successfully added to your 
